FDA flags rare eye-stroke risk in GLP-1 drugs

The FDA issued a safety communication warning that GLP-1 receptor agonists may be associated with non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition causing sudden vision loss. The warning is based on post-marketing reports and observational data, not a confirmed causal link. This could affect prescribing patterns and add regulatory scrutiny to a blockbuster drug class, though the absolute risk remains low.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works